Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 320

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 320
---
 2024 and 2023. Lease Accounting- The Company recognizes right-of-uselease assets and corresponding liabilities arising from leasing activities over the requisite lease period. I ncome Taxes- Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. In December 2023, the FASB issued ASU No. 2023-09,Income Taxes ( Topic 740), which enhances the income tax disclosure requirements for public entities on an annual basis. Under ASU 2023-09,public entities will be required to disclose in their rate reconciliation, on an annual basis, both percentages and amounts in their reporting currency for certain categories in a tabular format, with accompanying qualitative disclosures. The amendments in ASU 2023-09are effective fiscal years beginning after December 31, 2024, and early adoption is permitted. The Company does not believe that the adoption of ASU 2023-09will have a material impact on its consolidated financial statements. Grant Income- In April 2021, the Company received approval from the Department of Health and Human Services for a $ 400,000grant. The grant was to conduct research for a low-costtopical immunotherapy formulation suitable for treating cervical cancer in low and middle-income countries and low resource settings in the U.S. Additionally, the Company assumed in the reverse merger a $ 2,000,000Business Innovation Research grant, a two year grant that was initiated in June 2023 and set to expire in June 2025, to support the clinical development of REM-001for the treatment of CMBC and had a remaining balance of $ 900,000as of the merger date. For the years ended December 31, 2024 and 2023, the Company recognized $ 58,000and $ 42,000of grant income in the consolidated statements of operations. F-7 8

TUHURA BIOSCIENCES, INC AND SUBSIDIARIES Notes to the consolidated financial statements For the years ended December 31, 2024, and 2023

Research and Development Expenses - Research and development consists of expenses incurred in connection with the discovery and development of product candidates. The Company expenses research and development costs as incurred.

Acquired In-ProcessResearch and Development - Acquired in-process research and development expenses consist